Effects Of Gan Zhi Kang Capsule On Expression Of Sterol Regulatory Element Binding Protein-1in Rats With Nonalcoholic Fatty Liver Disease

Research BackgroundNonalcoholic fatty liver disease (NAFLD), whose incidence in general population is20%-30%,is the most common chronic liver disease, as well as one of the greatest public health problemsof21st century. In terms of therapies, Western medicine, while lacking of direct effectivetherapeutic drugs, mainly attempts at helping people change the lifestyle, lose weight andimprove insulin resistance; Chinese traditional medicine, based on syndrome differentiation,treats the nonalcoholic fatty liver disease from such perspectives of liver constraint, qidepression to blood stasis and insufficiency of spleen etc.. According to basic theories of Chinesemedicine, we figure out that the gan zhi gang capsule has positive effect on smoothing liver,regulating qi, activating blood, dissolving stasis, nourishing spleen and resolving phlegm. Weaim to investigate the effect of gan zhi kang capsule on the expression of sterol regulatoryelement binding protein-1(SREBP-1) in rats with NAFLD, detect how much the contents ofserum alanine aminotransferase(ALT), observe the pathomorphology changes of liver in thenormal group, model group, moderate，high dose of gan zhi kang capsule treated group andSilibinin group; aspartate aminotransferase (AST), triglycerides(TG), total cholesterol (TC)and hepatic TG, TC are in moderate and high dose of gan zhi kang capsule treated group and theSilibinin group the normal group, model group, and study the change of serum to discuss theeffect of gan zhi kang capsule on treating dysbolism of intrahepatic fatty acids when NAFLDattacks.MethodForty SD rats were randomly divided into normal group, model group, the Silibinin groupmoderate and high dose of gan zhi kang capsule treated group with8for each group. Besides fedwith high fat diet which contains88%fodder,2%cholesterol and10%lard, the rats in treated group were intervened by different doses of gan zhi kangcapsule and Silibinin group every day.After twelve weeks, all the rats were sacrificed to measure the contents of serum alanineaminotransferase (ALT), aspartate aminotransferase (AST), triglycerides(TG), total cholesterol(TC) and the hepatic TG, TC, then made statistical analysis of the data. Byimmune-histochemistry, we detected the change of the expression of SREBP-1in liver in everygroup and compared the differences. Observe the pathomorphology change of liver and scorethat through HE; Liver index calculation: weigh the rats and their livers; Liver index calculationformula: Liver weight/weight*100%ResultsCompared with the normal group, the serum ALT, AST, TG, TC, Liver index;Liverweight;weight and the hepatic TG, TC in model group were markedly higher, which isstatistically significant(P=0.001);then compared with the model group, the serum ALT,AST, TG, TC, Liver index;Liverweight;weight and the hepatic TG, TC in gan zhi kang capsule treated group and the Silibiningroup decreased, which is also statistically significant(P <0.05). The SREBP-1expression inmodel group increased significantly when compared with normal group and that in gan zhi kangcapsule treated groups and the Silibinin group reduced significantly when compared withmodel group.compared with the Silibinin group the serum ALT, AST, TG, TC, Liver index;Liverweight;weight and the hepatic TG, TC in gan zhi kang capsule treated group were not difference,which is not statistically significant(P>0.05).ConclusionThat the serum ALT, AST, TG, TC and the hepatic TG, TC in model group were markedly higher,may be one of causes that lead to those rats’ fatty change of the Ⅲ area bullous iver acinus orliver cell which is mainly bullous. That the SREBP-1expression in model group increasedsignificantly, may be the mechanism in metabolic disturbance of intrahepatic fatty acids. Thatserum ALT,AST, TG, TC, Liver index;Liver weight;weigh; the hepatic TG, TC and SREBP-1ingan zhi kang capsule treated group and the Silibinin group all decreased, indicates the gan zhikang capsule exerts protective effects against NAFLD in rats induced by high fat diet through itsinhibiting the expression of SREBP-1. It has supplied forceful experimental evidence for study on mechanism in metabolic disturbance of intrahepatic fatty acids and treatment on NAFLD withfurther clinical use gan zhi kang capsule to prevent nonalcoholic steatohepatitis and cirrhosisdevelopment.